ORCID "0000-0002-0443-6966" Makale Koleksiyonu için listeleme
-
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Gürbüz, Mustafa; Kutlu, Yasin; Akkuş, Erman; Köksoy, Elif Berna; Köse, Naziyet; Öven, Bala Başak; Oyan Uluç, Başak; Demiray, Atike Gökçen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Üskent, Necdet; Akbaş, Sinem; Selçukbiricik, Fatih; İnal, Ali; Bilici, Ahmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Ünal, Çağlar; Hizal, Mutlu; Şendur, Mehmet Ali Nahit; Korkmaz, Mustafa; Karadurmuş, Nuri; Ertürk, İsmail; Göksu, Sema Sezgin; Tatlı, Ali Murat; Güven, Deniz Can; Kılıçkap, Saadettin; Paksoy, Nail; Aydıner, Adnan; Yeşil Çınkır, Havva; Özkul, Özlem; Öztürk, Akın; Ballı, Sevinç; Kemal, Yasemin; Erdoğan, Atike Pınar; Er, Özlem; Yumuk, Perran Fulden; Demirkazık, Ahmet (Springer, 2022)Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In ... -
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
İlhan, Yusuf; Tatlı, Ali Murat; Teker, Fatih; Önder, Arif Hakan; Köse, Fatih; Geredeli, Çağlayan; Karaağaç, Mustafa; Kaplan, Muhammet Ali; İnanç, Mevlüde; Göktaş Aydın, Sabin; Kargı, Ayşegül; Arak, Hacı; Özturk, Banu; Beşen, Ali Ayberk; Selvi, Oğuzhan; Korkmaz, Mustafa; Oruç, Zeynep; Bozkurt, Oktay; Bilici, Ahmet; Bayram, Selami; Dae, Shute Ailia; Özdoğan, Mustafa; Coşkun, Hasan Şenol; Sezgin Göksu, Sema (BMJ Publishing Group, 2022)OBJECTIVE: Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In ... -
Factors predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer
Yıldırım, Emine; Bektaş, Sibel; Göktaş Aydın, Sabin; Er, Ahmet Muzaffer; Yanık, İrem; Özkan Gümüşkaya, Perihan; Yılmaz, Barbaros Utku; Bilici, Ahmet; Öncel, Mustafa (Istanbul University, 2022)Objective: In the treatment of local advanced gastric cancer (LAGC), it is recommended to start with neoadjuvant chemotherapy (NAC). Although the benefits of NAC have been shown, it is still not fully understood which ... -
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
Bilici, Ahmet; Ölmez, Ömer Fatih; Kaplan, Muhammed Ali; Öksüzoğlu, Berna; Sezer, Ahmet; Karadurmuş, Nuri; Çubukçu, Erdem; Şendur, Mehmet Ali Nahit; Aksoy, Sercan; Demirci, Umut (Taylor & Francis Ltd, 2023)AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ... -
The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors
Dişel, Umut; Köse, Fatih; Bilici, Ahmet; Özgüroğlu, Mustafa; Sağlam, Sezer; Şeker, Mesut; Aksoy, Sercan; Tek, İbrahim; Mandel, Nil Molinas; Demir, Gökhan; Arslan, Çağatay; Demiray, Mutlu; Öztürk, Mehmet Akif; Salepçi, Taflan; Eralp, Yeşim; Selçukbiricik, Fatih; Temizaş, Gökçe; Fidan, Ebru Gül (Turkiye Klinikleri, 2022)Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact ... -
Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Çalış, Elif; Ölmez, Ömer Fatih; Karcı, Ebru (Lippincott Williams & Wilkins, 2023)... -
Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Çalış, Elif; Kutlu, Yasin; Hamdard, Jamshid; Muğlu, Harun; Ölmez, Ömer Fatih; Karcı, Ebru; Açıkgöz, Özgür (Elsevier B.V., 2023)Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, ... -
Meme kanserli hastalarda kemoterapi sonrası bilişsel fonksiyonların aktivite performansı ve aktivite katılım üzerine olan etkisi
Akdemir, Gülhizar; Ünsal, Esra; Tarakçı, Devrim; Bilici, Ahmet; Ölmez, Fatih Ömer; Yıldız, Özcan (AVES, 2021)Amaç: Bilişsel fonksiyon problemleri kemoterapinin en yaygın yan etkileri arasında yer almaktadır. Bireyler tedavi bittikten sonra da bilişsel fonksiyon bozuklukları yaşamaya devam etmektedir. Meme kanseri atlatan bireyler ... -
Merkel cell carcinoma in Turkey: A multicentric study
Yıldız, Fatih; Demirci, Umut; Küçükarda, Ahmet; Büyükşimşek, Mahmut; Sakalar, Teoman; Öztürk Topçu, Türkan; Aslan, Ferit; Tufan, Gülnihal; Aydın, Övgü; Turna, Hande; Akgül Babacan, Nalan; Başoğlu, Tugba; Kurt, Bediz; Yıldız, Birol; Eren, Tülay; Demiray, Atike Gökçen; Gümüşay, Özge; Arslan, Çağatay; Özdemir, Nuriye; Ürün, Yüksel; Baykara, Meltem; Turan, Nedim; Uysal, Mükremin; Bilici, Ahmet; Kavgacı, Halil; Çiçin, İrfan; Kılıçkap, Saadettin; Paydaş, Semra (Wolters Kluwer Medknow Publications, 2021)Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of ... -
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
Kutlu, Yasin; Göktaş Aydın, Sabin; Bilici, Ahmet; Öven, Bala Başak; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Hamdard, Jamshid (NLM (Medline), 2023)Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy ... -
Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
Açıkgöz, Özgür; Çakan, Burçin; Demir, Tarık; Bilici, Ahmet; Öven, Bala Başak; Hamdard, Jamshid; Olmuşçelik, Oktay; Ölmez, Ömer Fatih; Şeker, Mesut; Yıldız, Özcan (Lippincott Williams & Wilkins, 2021)The aim of this study was to investigate the predictive and prognostic value of PLR, and the relationship between PLR and tumor localization. A total of 229 patients with de-novo metastatic CRC were retrospectively analyzed. ... -
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Göktaş Aydın, Sabin; Kutlu, Yasin; Muğlu, Harun; Aydın, Ahmet; Açıkgöz, Özgür; Hamdard, Jamshid; Karcı, Ebru; Bilici, Ahmet; Ölmez, Ömer Fatih; Yıldız, Özcan (Springer, 2024)Background: Prostate cancer is a prevalent cancer in men worldwide, and castration-resistant prostate cancer (CRPC) is characterized by disease progression despite androgen deprivation therapy. While clinical and prognostic ... -
Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: Single center experience from Turkey
Açıkgöz, Özgür; Yıldız, Anıl; Bilici, Ahmet; Ölmez, Ömer Fatih; Basım, Pelin; Çakır, Aslı (Lippincott Williams and Wilkins, 2022)The aim of this study was to investigate the predictive value of PLR and NLR as an indicator of pathological complete response (pCR) in patients with breast cancer after NACT. One hundred thirty-nine patients with early ... -
Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
Göktaş Aydın, Sabin; Kavak, Engin Eren; Topçu, Atakan; Bayramgil, Ayberk; Akgül, Fahri; Kahraman, Seda; Aykan, Musa Barış; Altıntaş, Yunus Emre; Helvacı, Kaan; Ürün, Yüksel; Bilici, Ahmet; Şeker, Mesut (Association of Basic Medical Sciences of FBIH, 2023)Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing ... -
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes
Yıldız, Anıl; Bilici, Ahmet; Açıkgöz, Özgür; Hamdard, Jamshid; Basım, Pelin; Çakır, Tansel; Çakır, Aslı; Ölmez, Ömer Fatih; Gezen, Cem; Yıldız, Özcan (Taylor and Francis Ltd., 2024)The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to ... -
Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
Bilici, Ahmet; Uysal, Mükremin; Menekşe, Serkan; Akın, Semih; Yıldız, Fatih; Turan, Merve; Sezgin Göksu, Sema; Beypınar, İsmail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Başaran, Gül; Ölmez, Ömer Fatih; Avcı, Nilüfer; Tural, Deniz; Sakin, Abdullah; Türker, Sema; Demir, Atakan; Temiz, Süleyman; Kaplan, Muhammed Ali; Doğan, Mutlu; Tanrıverdi, Özgür; Bilgetekin, İrem; Yeşil Çınkır, Havva; Açıkgöz, Özgür; Paydaş, Semra; Uslu, Rüçhan; Turhal, Serdar (Taylor & Francis Inc, 2022)Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Açıkgöz, Özgür; Kutlu, Yasin; Bilici, Ahmet; Hamdard, Jamshid; Ölmez, Ömer Fatih; Yıldız, Özcan (Ankara Society of Hematology and Oncology, 2021)Background: Immunotherapy agents such as atezolizumab and nivolumab are appropriate option for non-small cell lung cancer (NSCLC) accounts in the absence of driver mutation, regardless of PDL-1 expression in second and ... -
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Açıkgöz, Özgür; Sezer, Ahmet; Gürbüz, Mustafa; Ak, Naziye; Yücel, Şebnem; Ayhan, Murat; Erol, Cihan; Demirkıran, Aykut; Mandel, Nil Molinas; Shbair, Abdallah; Gökmen, İvo; Başoğlu, Tuğba; Paydaş, Semra; Demiray, Atike Gökçen; İriağaç, Yakup; Şakalar, Teoman; Zeynelgil, Esra; Tatlı, Ali Murat; Bahçeci, Aykut; Güven, Deniz Can; Caner, Burcu; Can, Alper; Gülmez, Ahmet; Karakaş, Yusuf; Yalçın, Bülent; Demirkazık, Ahmet; Bilici, Ahmet; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Springer, 2022)Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ... -
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: A retrospective Turkish oncology group (TOG) study
Bilici, Ahmet; Koca, Sinan; Karaağaç, Mustafa; Aydın Göktaş, Sabin; Eraslan, Emrah; Kaplan, Muhammed Ali; Ocak, Birol; Göksu, Sema Sezgin; Paydaş, Semra; Akgül, Fahri; Derin, Sümeyye; Ergün, Yakup (Springer, 2023)Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS). Patients and methods: This multicenter study is based on retrospective ... -
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
Erol, Vedat Buğra; Göktaş Aydın, Sabin; Bilici, Ahmet; Çakır, Aslı; Açıkgöz, Özgür; Ölmez, Ömer Fatih; Basım, Pelin (Taylor and Francis Ltd., 2023)To evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were ...